Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03949244 · ClinicalTrials.gov registry record · Phase 4

Nailfold Capillary Blood Flow With Latanoprost Bunod

A Phase 4 study, sponsored by Icahn School of Medicine at Mount Sinai.

Completed
Registry status
Phase 4
Development phase
47
Enrollment target

NCT03949244 is a Phase 4 study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 47 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03949244, a Phase 4 study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.

COMPLETED
Registry status
Phase 4
Development phase
47 participants
Enrollment target

Study Summary

The purpose of this study is to look at the relationship of small blood vessels irregularities observed with an imaging system called video nailfold capillaroscopy in people with primary open-angle glaucoma. Nailfold capillaroscopy (NFC) is a video camera with a magnifying lens used for studying the movement of blood in small blood vessels. It is simple, safe and does not penetrate the skin. The skin fold that is at the tip of the finger is called the "nailfold". NFC has been used to assess blood vessel narrowing in patients with glaucoma.

Interventions

  • DRUG Latanoprost 0.005%
  • DRUG Latanoprost bunod 0.024%
  • DRUG Normal saline 0.9%
  • DIAGNOSTIC_TEST Nailfold capillaroscopy

Trial Details

FieldValue
Enrollment Target 47 participants
Start Date 2019-08-15
Est. Completion 2020-10-01
Phase Phase 4

What the Registry Record Tells You About NCT03949244

The ClinicalTrials.gov registry entry for NCT03949244 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which Latanoprost 0.005% is the first listed.

NCT03949244 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03949244 about?

NCT03949244 is a clinical study titled "Nailfold Capillary Blood Flow With Latanoprost Bunod". The purpose of this study is to look at the relationship of small blood vessels irregularities observed with an imaging system called video nailfold capillaroscopy in people with primary open-angle glaucoma. Nailfold capillaroscopy (NFC) is a video camera with a magnifying lens used for studying the...

What is the current status of trial NCT03949244?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 47 participants. The study started on 2019-08-15. Estimated completion is 2020-10-01.

What interventions are being tested in trial NCT03949244?

The interventions under investigation include: Latanoprost 0.005% (DRUG), Latanoprost bunod 0.024% (DRUG), Normal saline 0.9% (DRUG), Nailfold capillaroscopy (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT03949244?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.